<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159633">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01745094</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-110</org_study_id>
    <nct_id>NCT01745094</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients</brief_title>
  <official_title>Post-Marketing Clinical Study of Mirabegron -Add-on Therapy With Mirabegron in Patients With Overactive Bladder Under Treatment With Solifenacin-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of concomitant use of
      mirabegron in patients with overactive bladder under treatment with solifenacin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study will be a total of 18 weeks including a 2-week screening period
      and 16 week treatment period. At week 8 visit, the dose of mirabegron can be increased based
      on agreement of the subject if mirabegron, in the opinion of the investigator or
      sub-investigator, is not fully effective.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vial signs labo-tests, 12-lead ECGs, QTc-intervals Urine volume and uroflowmetry</measure>
    <time_frame>for 16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in OABSS (OverActive Bladder Symptom Score)</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in OAB-q (OverActive Bladder questionnaire) short form (QAB-q SF) score</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of micturition episodes per 24 hour</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urgency episodes per 24 hours</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urinary incontinence episodes per 24 hours</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean volume voided per micturition</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Concomitant Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concomitant administration of mirabegron to solifenacin treated patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>Concomitant Group</arm_group_label>
    <other_name>YM178</other_name>
    <other_name>Betanis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <description>oral</description>
    <arm_group_label>Concomitant Group</arm_group_label>
    <other_name>YM905</other_name>
    <other_name>Vesicare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female: postmenopausal OAB outpatient

          -  Male: OAB outpatient who has no wish to have children in the future

          -  Patient has been under treatment with solifenacin at a stable dose once daily for at
             least 4 weeks prior to the study

          -  Patient has a total OABSS score of ≥3 points and a Question 3 score ≥2 points

        Exclusion Criteria:

          -  Patient has a residual urine volume of ≥100 mL or a maximum flow rate &lt;5 mL/s, or
             patients with benign prostatic hyperplasia, or lower urinary tract obstruction

          -  Patient has serious heart disease (myocardial infarction, cardiac failure,
             uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver
             disease, kidney disease, immunological disease, lung disease, etc. or patient has
             malignant tumor (except for malignant tumor that has not been treated for at least 5
             y before the start of the screening period with no risk of recurrence)

          -  Patient has received surgical therapy that may affect the urinary tract function
             within 24 wk before the start of the screening period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Administration Dept.</last_name>
    <email>clintrialtrials_info@jp.astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 6, 2012</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solifenacin</keyword>
  <keyword>mirabegron</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
